欧盟批准Novartis的Kisqali早期乳腺癌治疗,将复发风险降低25.1%。 EU approves Novartis' Kisqali for early breast cancer, reducing recurrence risk by 25.1%.

欧洲联盟委员会批准了诺华氏菌的Kisqali,并配以一种芳香酶抑制剂,用于治疗高危复发风险的HR阳性、HER2-阴性早期乳腺癌患者。 The European Commission has approved Novartis' Kisqali in combination with an aromatase inhibitor for treating HR-positive, HER2-negative early breast cancer patients at high risk of recurrence. 根据第三阶段的NATALEE试验,这种治疗比仅内分泌疗法就减少了25.1%的疾病复发风险。 Based on the Phase III NATALEE trial, this treatment reduces the risk of disease recurrence by 25.1% compared to endocrine therapy alone. 这项批准的目的是改善欧洲更多病人的治疗结果。 This approval aims to improve outcomes for a larger group of patients in Europe.